Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 55

Cited In for PubMed (Select 19666590)

1.

MR1-restricted mucosal associated invariant T (MAIT) cells in the immune response to Mycobacterium tuberculosis.

Gold MC, Napier RJ, Lewinsohn DM.

Immunol Rev. 2015 Mar;264(1):154-66. doi: 10.1111/imr.12271.

PMID:
25703558
2.

Qualification of a whole blood intracellular cytokine staining assay to measure mycobacteria-specific CD4 and CD8 T cell immunity by flow cytometry.

Kagina BM, Mansoor N, Kpamegan EP, Penn-Nicholson A, Nemes E, Smit E, Gelderbloem S, Soares AP, Abel B, Keyser A, Sidibana M, Hughes JE, Kaplan G, Hussey GD, Hanekom WA, Scriba TJ.

J Immunol Methods. 2015 Feb;417:22-33. doi: 10.1016/j.jim.2014.12.003. Epub 2014 Dec 16.

PMID:
25523923
3.

Tuberculosis vaccines and prevention of infection.

Hawn TR, Day TA, Scriba TJ, Hatherill M, Hanekom WA, Evans TG, Churchyard GJ, Kublin JG, Bekker LG, Self SG.

Microbiol Mol Biol Rev. 2014 Dec;78(4):650-71. doi: 10.1128/MMBR.00021-14.

PMID:
25428938
4.

Modeling of novel diagnostic strategies for active tuberculosis - a systematic review: current practices and recommendations.

Zwerling A, White RG, Vassall A, Cohen T, Dowdy DW, Houben RM.

PLoS One. 2014 Oct 23;9(10):e110558. doi: 10.1371/journal.pone.0110558. eCollection 2014.

5.

Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries.

Knight GM, Griffiths UK, Sumner T, Laurence YV, Gheorghe A, Vassall A, Glaziou P, White RG.

Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):15520-5. doi: 10.1073/pnas.1404386111. Epub 2014 Oct 6.

6.

Modelling the cost-effectiveness of a new infant vaccine to prevent tuberculosis disease in children in South Africa.

Channing L, Sinanovic E.

Cost Eff Resour Alloc. 2014 Sep 16;12:20. doi: 10.1186/1478-7547-12-20. eCollection 2014.

7.

Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis.

Roy A, Eisenhut M, Harris RJ, Rodrigues LC, Sridhar S, Habermann S, Snell L, Mangtani P, Adetifa I, Lalvani A, Abubakar I.

BMJ. 2014 Aug 5;349:g4643. doi: 10.1136/bmj.g4643. Review.

8.

Latent Tuberculosis: Models, Computational Efforts and the Pathogen's Regulatory Mechanisms during Dormancy.

Magombedze G, Dowdy D, Mulder N.

Front Bioeng Biotechnol. 2013 Aug 27;1:4. eCollection 2013. Review.

9.

A user-friendly, open-source tool to project impact and cost of diagnostic tests for tuberculosis.

Dowdy DW, Andrews JR, Dodd PJ, Gilman RH.

Elife. 2014 Jun 4;3. doi: 10.7554/eLife.02565.

10.

The ongoing challenge of latent tuberculosis.

Esmail H, Barry CE 3rd, Young DB, Wilkinson RJ.

Philos Trans R Soc Lond B Biol Sci. 2014 May 12;369(1645):20130437. doi: 10.1098/rstb.2013.0437. Print 2014. Review.

11.

After 2015: infectious diseases in a new era of health and development.

Dye C.

Philos Trans R Soc Lond B Biol Sci. 2014 May 12;369(1645):20130426. doi: 10.1098/rstb.2013.0426. Print 2014. Review.

12.

Population-level impact of shorter-course regimens for tuberculosis: a model-based analysis.

Fofana MO, Knight GM, Gomez GB, White RG, Dowdy DW.

PLoS One. 2014 May 9;9(5):e96389. doi: 10.1371/journal.pone.0096389. eCollection 2014.

13.

Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.

Hatherill M, Geldenhuys H, Pienaar B, Suliman S, Chheng P, Debanne SM, Hoft DF, Boom WH, Hanekom WA, Johnson JL.

Vaccine. 2014 Jun 30;32(31):3982-8. doi: 10.1016/j.vaccine.2014.04.084. Epub 2014 May 9.

PMID:
24814553
14.

Pregnancy differentially impacts performance of latent tuberculosis diagnostics in a high-burden setting.

Mathad JS, Bhosale R, Sangar V, Mave V, Gupte N, Kanade S, Nangude A, Chopade K, Suryavanshi N, Deshpande P, Kulkarni V, Glesby MJ, Fitzgerald D, Bharadwaj R, Sambarey P, Gupta A.

PLoS One. 2014 Mar 21;9(3):e92308. doi: 10.1371/journal.pone.0092308. eCollection 2014.

15.

The use of supplementary immunisation activities to improve uptake of current and future vaccines in low-income and middle-income countries: a systematic review protocol.

Kagina BM, Wiysonge CS, Machingaidze S, Abdullahi LH, Adebayo E, Uthman OA, Hussey GD.

BMJ Open. 2014 Feb 18;4(2):e004429. doi: 10.1136/bmjopen-2013-004429.

16.

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.

Tameris M, Geldenhuys H, Luabeya AK, Smit E, Hughes JE, Vermaak S, Hanekom WA, Hatherill M, Mahomed H, McShane H, Scriba TJ.

PLoS One. 2014 Feb 3;9(2):e87340. doi: 10.1371/journal.pone.0087340. eCollection 2014.

17.

Potential cost-effectiveness of a new infant tuberculosis vaccine in South Africa--implications for clinical trials: a decision analysis.

Ditkowsky JB, Schwartzman K.

PLoS One. 2014 Jan 15;9(1):e83526. doi: 10.1371/journal.pone.0083526. eCollection 2014.

18.

Elimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine against tuberculosis by lyophilization.

Orr MT, Kramer RM, Barnes L 5th, Dowling QM, Desbien AL, Beebe EA, Laurance JD, Fox CB, Reed SG, Coler RN, Vedvick TS.

J Control Release. 2014 Mar 10;177:20-6. doi: 10.1016/j.jconrel.2013.12.025. Epub 2013 Dec 29.

19.

Optimal triage test characteristics to improve the cost-effectiveness of the Xpert MTB/RIF assay for TB diagnosis: a decision analysis.

van't Hoog AH, Cobelens F, Vassall A, van Kampen S, Dorman SE, Alland D, Ellner J.

PLoS One. 2013 Dec 18;8(12):e82786. doi: 10.1371/journal.pone.0082786. eCollection 2013.

20.

ESAT-6 (EsxA) and TB10.4 (EsxH) based vaccines for pre- and post-exposure tuberculosis vaccination.

Hoang T, Aagaard C, Dietrich J, Cassidy JP, Dolganov G, Schoolnik GK, Lundberg CV, Agger EM, Andersen P.

PLoS One. 2013 Dec 12;8(12):e80579. doi: 10.1371/journal.pone.0080579. eCollection 2013.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk